Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-Month outcomes

American Journal of Psychiatry

Volumn 163, Issue 12, 2006, Pages 2096-2102

  Robinson, Delbert G ^a   Woerner, Margaret G ^b   Napolitano, Barbara ^b   Patel, Raman C ^b   Sevy, Serge M ^b   Gunduz Bruce, Handan ^b   Soto Perello, Jose M ^b   Mendelowitz, Alan ^b   Khadivi, Ali ^b   Miller, Rachel ^b   McCormack, Joanne ^b   Lorell, Beth S ^b   Lesser, Martin L ^b   Schooler, Nina R ^b   Kane, John M ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; RISPERIDONE; VALPROATE SEMISODIUM;

ADULT; AKATHISIA; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33846305400     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2006.163.12.2096     Document Type: Article

References (28)

1. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer RM: Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine versus chlorpromazine. Neuropsychopharmacology 2003; 28:995-1003
2. Emsley RA, the Risperidone Working Group: Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull 1999; 25:721-729
3. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G, Early Psychosis Global Working Group: Risperidone and haloperidol in first episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162:947-953
4. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM, HGDH Study Group: Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160:1396-1404
5. Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N: Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64: 1075-1080
6. Lieberman JA, Stroup TS, McEnvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
7. Robinson D, Woerner M, Schooler N: Intervention research in psychosis: issues related to clinical assessment. Schizophr Bull 2000; 26:551-556
8. Robinson DG, Woerner MG, Delman H, Kane JM: Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005; 31:705-722
9. Lieberman JA, Stroup TS, Davis SM: Antipsychotic drugs and schizophrenia (letter). N Engl J Med 2005; 354: 300
10. Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35:51-68
11. Safer DJ: A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 2004; 24:429-436
12. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17:405-418
13. Conley RR, Mahmoud R: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158:765-774
14. Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G: International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2003; 11: 638-647
15. Freedman R: The choice of antipsychotic drugs for schizophrenia. N Engl J Med 2005; 353:1286-1288
16. Ball MP, Coons VB, Buchanan RW: A program for treating olanzapine-related weight gain. Psychiatr Serv 2001; 52:967-969
17. Cohen S, Glazewski R, Khan S, Khan A: Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. J Clin Psychiatry 2001; 62:114-116
18. Gracious BL, Krysiak TE, Youngstrom EA: Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. J Child Adolesc Psychopharmacol 2002; 12:249-257
19. Morrison JA, Cottingham EM, Barton BA: Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002; 159:655-657
20. Yanovski SZ, Yanovski JA: Obesity. N Engl J Med 2002; 346:591-602
21. Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld-Hamm B, Stern R: A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003; 54: 1155-1157
22. Nemeroff CB: Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 2003; 64:532-539
23. Birt J: Management of weight gain associated with antipsychotics. Ann Clin Psychiatry 2003; 15:49-58
24. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11:722-733
25. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med 2000; 160:898-904
26. American Diabetes Association: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2001; 24 (suppl 1):S5-S20
27. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348:1625-1638
28. Brown S: Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997; 171:502-508